Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • diabetology

    Tag: diabetology

    You Searched For "diabetology"
    Lupin gets EIR from USFDA for Oral Dosage facility in Aurangabad

    Lupin gets EIR from USFDA for Oral Dosage facility in Aurangabad

    Medical Dialogues Bureau5 Aug 2019 4:15 AM GMT
    Lupin Ltd's Aurangabad facility is involved in the manufacture of Oral Solid Dosage, Oral Liquid and Powder for Oral Suspension products for the US Mar...
    Dr Reddys launches OTC brand equivalent of Mucinex D ER tablets to treat phlegm

    Dr Reddys launches OTC brand equivalent of Mucinex D ER tablets to treat phlegm

    Medical Dialogues Bureau10 July 2019 4:34 AM GMT
    The Mucinex D brand and store brands had combined US sales of approximately USD 71 million MAT (moving annual turnover) for the most recent 12 months e...
    Lupin unveils generic Imatinib Mesylate tablets to treat types of cancer

    Lupin unveils generic Imatinib Mesylate tablets to treat types of cancer

    Medical Dialogues Bureau10 July 2019 4:30 AM GMT
    Lupin's Imatinib Mesylate Tablets, 100mg (base) and 400mg (base), is the generic version of Novartis Pharmaceuticals Corporation's (Novartis) Gleevec T...
    Cipla to acquire 11.71 percent stake in Wellthy Therapeutics

    Cipla to acquire 11.71 percent stake in Wellthy Therapeutics

    Garima20 Feb 2019 9:25 AM GMT
    New Delhi: Drug major Cipla Monday said it has inked a pact to acquire 11.71 per cent stake in Wellthy Therapeutics. Golden cross Pharma, a...

    Popular Stories

    • Email: info@medicaldialogues.in
    • Phone: 011 - 4372 0751

    Website Last Updated On : 27 May 2022 6:45 AM GMT
    Company
    • About Us
    • Contact Us
    • Our Team
    • Reach our Editor
    • Feedback
    • Submit Article
    Ads & Legal
    • Advertise
    • Advertise Policy
    • Terms and Conditions
    • Privacy Policy
    • Editorial Policy
    • Comments Policy
    • Disclamier

    This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
    verify here.

    Search only trustworthy HONcode health websites:

    Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

    Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

    © 2020 - Medical Dialogues. All Rights Reserved.
    Powered By: Hocalwire
    We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok
    X
    X